Vericel Corporation (VCEL)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.22 (-0.39%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Vericel Corporation (VCEL)
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Key Insights

Critical company metrics and information
  • Share Price

    $56.37
  • Market Cap

    $2.78 Billion
  • Total Outstanding Shares

    49.36 Million Shares
  • Total Employees

    314
  • Dividend

    No dividend
  • IPO Date

    February 4, 1997
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.vcel.com

Historical Stock Splits

If you bought 1 share of VCEL before October 16, 2013, you'd have 0.05 shares today.
Execution DateSplit Amount
October 16, 20131-for-20 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-72.47 Million
Net Cash Flow$-13.21 Million
Net Cash Flow From Investing Activities$-72.47 Million
Net Cash Flow From Financing Activities$13.25 Million
Net Cash Flow From Operating Activities$46.01 Million
Net Cash Flow From Operating Activities, Continuing$46.01 Million
Net Cash Flow, Continuing$-13.21 Million
Net Cash Flow From Financing Activities, Continuing$13.25 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Earnings Per Share$0.07
Research and Development$24.77 Million
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss$3.55 Million
Cost Of Revenue$64.73 Million
Operating Income/Loss$-1.23 Million
Gross Profit$162.12 Million
Costs And Expenses$222.20 Million
Operating Expenses$163.34 Million
Benefits Costs and Expenses$222.20 Million
Income/Loss From Continuing Operations After Tax$3.55 Million
Revenues$226.84 Million
Basic Average Shares$48.69 Million
Net Income/Loss Attributable To Parent$3.55 Million
Income/Loss From Continuing Operations Before Tax$4.65 Million
Income Tax Expense/Benefit$1.10 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Available To Common Stockholders, Basic$3.55 Million
Diluted Average Shares$48.69 Million
Diluted Earnings Per Share$0.07
Nonoperating Income/Loss$5.88 Million
Selling, General, and Administrative Expenses$138.57 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Inventory$15.76 Million
Assets$390.40 Million
Other Current Assets$174.76 Million
Noncurrent Liabilities$91.59 Million
Current Liabilities$41.35 Million
Equity$257.47 Million
Accounts Payable$20.88 Million
Current Assets$190.52 Million
Wages$3.09 Million
Liabilities And Equity$390.40 Million
Liabilities$132.93 Million
Equity Attributable To Noncontrolling Interest$0.00
Noncurrent Assets$199.88 Million
Other Current Liabilities$17.38 Million
Equity Attributable To Parent$257.47 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.